Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 11/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20334477 | 0.86 | CFD (0.45) | CFDLMNAHTTKDM4ETSHR | |
| SCHEMBL19208156 | 0.86 | LMNA (0.46) | CFDLMNAHTTKDM4ETSHR | |
| SCHEMBL17023825 | 0.85 | CFD (0.56) | CFD | |
| SCHEMBL19208544 | 0.83 | LMNA (0.39) | CFDLMNAHTTKDM4ETSHR | |
| SCHEMBL20334288 | 0.79 | CFD (0.42) | CFDLMNATSHRRXFP1MEN1 | |
| SCHEMBL12479189 | 0.79 | LMNA (0.46) | CFDLMNAHTTKDM4ETSHR | |
| SCHEMBL20334307 | 0.79 | EGFR (0.43) | CFDTSHRRXFP1MEN1KMT2A | |
| SCHEMBL30378124 | 0.79 | EGFR (0.43) | CFDTSHRRXFP1MEN1KMT2A | |
| SCHEMBL30146875 | 0.77 | SMN1; SMN2 (0.41) | CFDLMNAHTTTSHRRXFP1 | |
| SCHEMBL19208678 | 0.77 | SMN1; SMN2 (0.41) | CFDLMNAHTTTSHRRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660876-B2 | Amino compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180177761-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660876-B2 | Amino compounds for treatment of medical disorders | CFD, CFH, F12 | CFD 1/4885LMNA 1013/4885HTT 2392/4885 |
| US-20180177761-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, CFH, F12 | CFD 1/4885LMNA 1013/4885HTT 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.